Sutro Biopharma, Inc.
STRO
$40.05
-$0.86-2.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 15.99% | -74.88% | -67.70% | -113.31% | -112.99% |
| Total Depreciation and Amortization | 1.47% | 6.88% | 6.35% | 5.67% | 5.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 187.48% | 610.66% | 21.37% | 39.56% | -12.90% |
| Change in Net Operating Assets | -666.28% | -2,418.70% | -693.43% | 161.59% | 125.89% |
| Cash from Operations | 7.47% | -110.47% | -233.08% | -68.75% | -71.61% |
| Capital Expenditure | 45.29% | 25.70% | -6.23% | -0.18% | 28.20% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -78.92% | 4.87% | 248.68% | 4,213.91% | 56,576.73% |
| Cash from Investing | -79.40% | 5.85% | 243.76% | 2,000.21% | 5,668.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 100.00% | 100.00% | 67.34% |
| Issuance of Common Stock | -99.62% | -99.62% | -98.64% | 3,129.83% | 588.10% |
| Repurchase of Common Stock | 34.77% | 40.41% | 23.87% | 23.73% | -3.88% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.95% | -99.91% | -98.81% | -22.19% | -31.62% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -209.21% | -217.17% | 81.46% | 1,401.72% | 449.75% |